Truvada (Tenofovir/emtricitabine), is a fixed-dose combination of two antiretroviral drugs, consisting of 300 milligrams of tenofovir and 200 milligrams of emtricitabine. The drug has been just approved for use as a pre-exposure prophylaxis against HIV infection. It significantly decreased the risk of contracting HIV. It is approved for non-infected men who have sex with multiple male partners.
Side effects include nausea, vomiting, dizziness and renal toxicity. Also, Lactic acidosis, steatosis and post treatment exacerbation of Hepatitis B.